Neuroprotective Natural Products for the Treatment of Parkinson's Disease by Targeting the Autophagy–Lysosome Pathway: A Systematic Review. (15th May 2017)

• Record Type: Journal Article
• Authors: Wang, Zi‐Ying; Liu, Jing‐Yi; Yang, Chuan‐Bin; Malampati, Sandeep; Huang, Ying‐Yu; Li, Mei‐Xiang; Li, Min; Song, Ju‐Xian
• Is Part Of: Phytotherapy research. Volume 31:Number 8(2017)
• Page Start: 1119
• Page End: 1127
• Publication Date: 2017-05-15
• Subjects: Parkinson's disease -- autophagy -- neuroprotection -- natural products; Materia medica, Vegetable -- Periodicals; Botany, Medical -- Periodicals; Medicinal plants -- Periodicals; Plant Extracts -- therapeutic use -- Periodicals; Plants, Medicinal -- Periodicals; 581.634
• DOI: 10.1002/ptr.5834
• Languages: English
• ISSNs: 0951-418X

Abstract

Abstract : The autophagy–lysosome pathway (ALP) is a primary means by which damaged organelles and long‐lived proteins are removed from cells and their components recycled. Impairment of the ALP has been found to be linked to the pathogenesis of Parkinson's disease (PD), a chronic neurodegenerative disorder characterized by the accumulation of protein aggregates and loss of dopaminergic neurons in the midbrain. In recent years, some active compounds derived from plants have been found to regulate the ALP and to exert neuroprotective effects in experimental models of PD, raising the possibility that autophagy enhancement may be an effective therapeutic strategy in PD treatment. In this review, we summarize recent findings of natural products that enhance ALP and thereby protect against PD. Research articles were retrieved from PubMed using relevant keywords in combination. Papers related to the topic were identified, and then the reliability of the experiments was assessed in terms of methodology. The results suggest that targeting the ALP with natural products is a promising strategy for PD treatment. However, risk of bias exists in some studies due to the defective methodology. Rigorous experimental design following the guidelines of autophagy assays, molecular target identification and in vivo efficacy evaluation is critical for the development of ALP enhancers for PD treatment in future studies. Copyright © 2017 John Wiley & Sons, Ltd.